Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?

BACKGROUND: Progressive multifocal leukoencephalopathy (PML) is one of the major risks of natalizumab therapy. Despite introduction of the currently employed PML risk stratification algorithm, the incidence of natalizumab-associated PML cases is not decreasing. OBJECTIVES: We addressed the following...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:PLoS One
Hlavní autoři: Krämer, Julia, Tenberge, Jan-Gerd, Kleiter, Ingo, Gaissmaier, Wolfgang, Ruck, Tobias, Heesen, Christoph, Meuth, Sven G.
Médium: Artigo
Jazyk:Inglês
Vydáno: Public Library of Science 2017
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5391008/
https://ncbi.nlm.nih.gov/pubmed/28406921
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0174858
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky